Skip to content

MyMD Prescribed drugs Broadcasts Upcoming Presentation of Late-Breaking Information for MYMD-1 on the 2022 British Society for Immunology Congress

MyMD Prescribed drugs, Inc. (Nasdaq: MYMD) (‘MyMD’ or ‘the Firm’), a scientific stage biopharmaceutical firm growing groundbreaking therapies for the therapy of significant and debilitating autoimmune and inflammatory ailments, has been invited to current late-breaking knowledge on the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Late-breaking summary entitled ‘Pharmacology and scientific profile of MYMD-1 (isomyosamine), an oral, selective, next-generation, tumor necrosis issue alpha (TNF-) inhibitor that crosses the blood mind barrier,’ is scheduled for poster presentation on December 6, 2022at 6pm GMT. Along with security and pharmacology knowledge, the presentation will embrace info on the anti-inflammatory results of MYMD-1 in a collagen antibody induced arthritis (CAIA) mannequin, which mimics options of arthritis in people.

We sit up for presenting these outcomes at BSI and are very happy that they’ve been chosen to be shared at this prestigious worldwide gathering of immunology consultants,’ stated chris chapman MD, president, director, and chief medical officer at MyMD Prescribed drugs. ‘We strongly consider within the potential of MYMD-1 as a next-generation TNF-inhibitor. With its differentiated oral administration and selectivity, it could in the future provide a significant therapeutic answer for sufferers with circumstances reminiscent of rheumatoid arthritis who will not be served by present TNF-inhibitors.’

MYMD-1 is an oral next-generation TNF-inhibitor with the potential to rework the way in which that TNF-based ailments are handled resulting from its selectivity and skill to cross the blood mind barrier. MyMD-1 is at the moment being evaluated in Section 2 research for sarcopenia/frailty, a results of the growing older course of, and has the potential to grow to be the primary drug authorized by FDA for the situation. MyMD Prescribed drugs is planning to check MYMD-1 in early-stage trials for rheumatoid arthritis (RA),

About MYMD-1

MYMD-1, an oral selective inhibitor of tumor necrosis factor-alpha (TNF-), a driver of power irritation, is being studied to gradual the growing older course of, stop sarcopenia and frailty, and lengthen wholesome lifespan. MYMD-1 has proven effectiveness in pre-clinical and scientific research in regulating the immune system. Not like different therapies, MYMD-1 has been proven in these research to selectively block TNF- when it turns into overactivated in autoimmune ailments and cytokine storms, however not block it from doing its regular job of being a primary responder to any routine sort of average an infection .

MYMD-1’s ease of oral dosing is one other differentiator in comparison with at the moment obtainable TNF-blockers, all of which require supply by injection or infusion. No FDA-approved TNF inhibitor has ever been dosed orally. As well as, the drug is just not immunosuppressive and has not been proven to trigger the intense unintended effects frequent with conventional therapies that deal with irritation. As a result of it may well cross the blood mind barrier and acquire entry to the central nervous system (CNS), MYMD-1 can also be positioned to be a attainable therapy for brain-related problems. Its mechanism of motion and efficacy in ailments together with a number of sclerosis (MS) and thyroiditis have been studied by collaborations with a number of tutorial establishments.

About MyMD Prescribed drugs

MyMD Prescribed drugs, Inc. (Nasdaq: MYMD), is a scientific stage biopharma firm growing groundbreaking therapies for the therapy of significant and debilitating autoimmune and inflammatory ailments. MyMD’s lead scientific candidate, MYMD-1, is an oral next-generation TNF-inhibitor with the potential to rework the way in which TNF-based ailments are handled resulting from its small molecule design and selectivity. MYMD-1 has the promise to offer significant therapeutic options to sufferers not served by present TNF-inhibitors and as a possible remedy for CNS-based inflammatory and autoimmune ailments. MYMD-1 has demonstrated the potential to gradual the growing older course of and lengthen wholesome lifespan. The corporate is evaluating MYMD-1 in Section 2 research for sarcopenia/frailty, a results of the growing older course of, and is at the moment planning for early-stage trials for rheumatoid arthritis (RA), with the potential to develop into different purposes.

MyMD’s second therapeutic candidate is Supera-CBD, a novel, artificial, non-toxic cannabidiol (CBD) analog that’s 8000 occasions stronger a CB2 agonist (activator) than plant-based CBD. Along with its potential function in managing dependancy, anxiousness, power ache and seizures, Supera-CBD has additionally been proven to have anti-inflammatory results.

Cautionary Assertion Relating to Ahead-Wanting Statements

This press launch could comprise forward-looking statements. These forward-looking statements contain identified and unknown dangers, uncertainties and different components which can trigger precise outcomes, efficiency, or achievements to be materially totally different from any anticipated future outcomes, efficiency, or achievements. Ahead-looking statements converse solely as of the date they’re made and none of MyMD nor its associates assume any responsibility to replace forward-looking statements. Phrases reminiscent of ‘anticipate,’ ‘consider,’ ‘may,’ ‘estimate,’ ‘count on,’ ‘could,’ ‘plan,’ ‘will,’ ‘would’ and different comparable expressions are supposed to determine these forward-looking statements. Essential components that might trigger precise outcomes to vary materially from these indicated by such forward-looking statements embrace, with out limitation: the timing of, and MyMD’s capability to, receive and keep regulatory approvals for scientific trials of MyMD’s pharmaceutical candidates; the timing and outcomes of MyMD’s deliberate scientific trials for its pharmaceutical candidates; the quantity of funds MyMD requires for its pharmaceutical candidates; elevated ranges of competitors; adjustments in political, financial or regulatory circumstances typically and within the markets by which MyMD operates; MyMD’s capability to retain and appeal to senior administration and different key staff; MyMD’s capability to rapidly and successfully reply to new technological developments; MyMD’s capability to guard its commerce secrets and techniques or different proprietary rights, function with out infringing upon the proprietary rights of others and stop others from infringing on MyMD’s proprietary rights and the impression of the continuing COVID-19 pandemic on MyMD’s outcomes of operations, marketing strategy and the worldwide financial system. A dialogue of those and different components with respect to MyMD is about forth within the Firm’s Annual Report on Type 10-Okay for the yr ended. December 31, 2021filed by MyMD on March 31, 2022as could also be supplemented or amended by the Firm’s Quarterly Reviews on Type 10-Q.Ahead-looking statements converse solely as of the date they’re made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.

Contact:

Robert Schatz

Cellphone: (646) 421-9523

E-mail: rschatz@mymd.com

.

Leave a Reply

Your email address will not be published. Required fields are marked *